Fisher Asset Management LLC Buys 764,963 Shares of Cullinan Therapeutics, Inc. $CGEM

Fisher Asset Management LLC boosted its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 2,125.0% in the third quarter, HoldingsChannel reports. The firm owned 800,961 shares of the company’s stock after buying an additional 764,963 shares during the period. Fisher Asset Management LLC’s holdings in Cullinan Therapeutics were worth $12,295,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Cullinan Therapeutics during the 2nd quarter worth about $95,289,000. Blue Owl Capital Holdings LP purchased a new stake in Cullinan Therapeutics in the 2nd quarter valued at $28,039,000. Dimensional Fund Advisors LP boosted its holdings in Cullinan Therapeutics by 6.7% during the first quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company’s stock worth $12,870,000 after purchasing an additional 57,259 shares during the last quarter. Boone Capital Management LLC bought a new position in shares of Cullinan Therapeutics in the second quarter valued at approximately $12,828,000. Finally, Elmind Capital LP bought a new position in Cullinan Therapeutics in the 2nd quarter valued at $12,564,900. Institutional investors and hedge funds own 86.31% of the company’s stock.

Analysts Set New Price Targets

CGEM has been the topic of several research analyst reports. Wall Street Zen downgraded Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Friday, October 2nd. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Cullinan Therapeutics in a research report on Friday, October 2nd. TD Cowen upgraded Cullinan Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Finally, BTIG Research upped their price target on shares of Cullinan Therapeutics from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.14.

View Our Latest Research Report on Cullinan Therapeutics

Insider Buying and Selling

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $12.36, for a total transaction of $49,440.00. Following the transaction, the insider owned 158,649 shares of the company’s stock, valued at $1,960,901.64. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 8.60% of the company’s stock.

Cullinan Therapeutics Stock Performance

Shares of CGEM opened at $10.28 on Monday. The firm’s 50-day simple moving average is $15.87 and its two-hundred day simple moving average is $15.80. The stock has a market cap of $667.39 million, a PE ratio of -3.35 and a beta of -0.03. Cullinan Therapeutics, Inc. has a fifty-two week low of $7.93 and a fifty-two week high of $23.19.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.10. Equities research analysts predict that Cullinan Therapeutics, Inc. will post -3.01 EPS for the current year.

Cullinan Therapeutics Company Profile

(Free Report)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company advances a pipeline of investigational medicines, including antibody-based therapies and T-cell engagers designed to direct immune responses against disease-related cells. Its programs include CLN-619, an antibody being studied for solid tumors; CLN-049, a T-cell engager targeting FLT3 for acute myeloid leukemia; and CLN-978, a CD19-targeting T-cell engager being developed for B-cell-mediated autoimmune diseases.

Recommended Stories

Want to see what other hedge funds are holding CGEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report).

Institutional Ownership by Quarter for Cullinan Therapeutics (NASDAQ:CGEM)

Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.